On June 4, Tempus AI rose 5.28% in regular trading, trading at $52.095/share, with trading volume of $163 million.

On the news front, Tempus AI recently received FDA approval for its tumor-only xT CDx next-generation sequencing platform for comprehensive genomic profiling of solid tumors. This milestone makes Tempus the first laboratory with FDA companion diagnostic approval for both tumor-only and tumor-normal genomic profiling. The company expects the approval to deliver an estimated $200 increase in average selling price starting in 2027, enabling migration of its entire DNA-based solid tumor product portfolio to the newly approved platform.

Additionally, the company introduced Lens, its next-generation agentic AI platform designed for oncology drug development, helping teams design better clinical trials and target patient subgroups. Tempus also presented new results on its multimodal tumor foundation model at the ASCO annual meeting, reinforcing its positioning at the intersection of AI and precision medicine.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)